Ascelia Pharma to meet FDA on Orviglance NDA after complete response letter

Reuters2026/08/17 09:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ascelia Pharma scheduled a Type A FDA meeting for Sept. 9, 2026 on the Orviglance New Drug Application.
Session will address the FDA’s Complete Response Letter issued July 2, 2026, covering clinical, quality, and regulatory topics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ascelia Pharma to meet FDA on Orviglance NDA after complete response letter

You may also like

Crypto prices